ABCD DTN Principles for CGM Choice in HCL systems: Clinical Need, Cost-Effectiveness, and Patient Safety
The use of HCL may enable provision of different CGM options. We agree that, provided accuracy standards are met, cost-effectiveness needs to be considered, and therefore encourage choice based on clinical need, with selection of the lowest cost device that meets an individual’s specific requirements. It is sensible that the lowest cost option should be the default choice, but where this does not meet an individual’s requirements an alternative should be available.
Clinical practice guidelines for management of lipids in adults with diabetic kidney disease
Updated: 2024
The primary purpose of these guidelines is to provide practical recommendations on lipid management for diabetologists, nephrologists, general practitioners and other members of the multidisciplinary team involved in the care of adults with diabetic kidney disease (DKD)
ABCD nationwide tirzepatide audit launched
The ABCD nationwide tirzepatide audit is now launched. ABCD members are invited to contribute to the audit.
As with all our audits, all contributors will be acknowledged in publications emanating from the audit and the biggest contributors will become co-authors.
You can also find out more about this and all the ABCD Audits within the Audits section of our website.
Objectives Tirzepatide Audit
ABCD is setting up a nationwide audit of tirzepatide (Mounjaro) in real clinical use in the UK. The aim will be to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials.
ABCD Tirzepatide Audit
About the ABCD tirzepatide audit
ABCD audits at the recent ATTD meeting in Amsterdam
The ABCD audit programme featured at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) which was held on 19-22 March 2025 in Amsterdam, Holland.
